Currently, there are 82.40M common shares owned by the public and among those 76.30M shares have been available to trade.
The company’s stock has a 5-day price change of -2.39% and -38.55% over the past three months. STRO shares are trading -52.45% year to date (YTD), with the 12-month market performance down to -51.31% lower. It has a 12-month low price of $1.70 and touched a high of $6.13 over the same period. STRO has an average intraday trading volume of 906.93K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -18.67%, -36.65%, and -47.89% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Sutro Biopharma Inc (NASDAQ: STRO) shares accounts for 69.77% of the company’s 82.40M shares outstanding.
It has a market capitalization of $168.22M and a beta (3y monthly) value of 1.13. The earnings-per-share (ttm) stands at -$1.62. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.66% over the week and 8.32% over the month.
Earnings per share for the fiscal year are expected to decrease by -62.82%, and -4.89% over the next financial year.
Looking at the support for the STRO, a number of firms have released research notes about the stock. BofA Securities stated their Buy rating for the stock in a research note on May 08, 2024, with the firm’s price target at $12. Deutsche Bank coverage for the Sutro Biopharma Inc (STRO) stock in a research note released on November 09, 2023 offered a Buy rating with a price target of $12. Oppenheimer was of a view on October 06, 2023 that the stock is Outperform, while Wells Fargo gave the stock Equal Weight rating on March 21, 2023, issuing a price target of $15- $8. Wells Fargo on their part issued Overweight rating on August 18, 2022.
